Blood Screening Market

Blood Screening Market by Technology (Nucleic Acid Amplification, (Real-Time PCR), ELISA (Chemiluminescence immunoassay), Rapid Test, Western Blot), Product (Instrument, Reagent & Kits, Software) & End User (Blood Bank, Hospital) - Global Forecast to 2026

Report Code: MD 3687 Nov, 2021, by marketsandmarkets.com

[235 Pages Report] The global blood screening market is projected to reach USD 3.8 billion by 2026 from USD 2.5 billion in 2021, at a CAGR of 8.4%. Market growth is driven by the rising prevalence of infectious diseases, and the increase in need for donated blood.

Blood Screening Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 Impact on Global Blood screening Market

The emergence of the COVID-19 pandemic has changed the delivery of medical care across the world. The increased pressure due to the growing rate of hospitalization of COVID-19 patients had led to the re-profiling of many hospitals and departments for treating patients with COVID-19. The COVID-19 outbreak led to curfews and lockdown worldwide, leading to stalled blood donations, decreased/canceled collection drives, and reduced demand for donated blood. It has mild-moderately affected the growth of the blood screening market. As stringencies with respect to curfews and social distancing become more liberal, the demand is expected to grow, creating a deficit in the market. However, governments globally are taking initiatives to increase donations during the forecasted period to meet the sudden rise in demand following the lockdown.

Moreover, the number of cancer patients are increasing which is also driving the need for donated blood. There is a need for blood and platelets during the treatment (chemotherapy) of a cancer patients, blood replacement (for blood cancer patients), and surgery. According to the US National Center for Biotechnology Information (NCBI), cancer patients account for 20% to 30% of blood transfusions. According to the Leukemia & Lymphoma Society (2021), an estimated combined total of 186,400 people in the US are expected to be diagnosed with leukemia, lymphoma, or myeloma in 2021. This is expected further to drive the demand for blood screening market.

Market Dynamics

Driver:  Increasing number of blood donations worldwide

There is an increase in need fot donated blood because of advancements in healthcare systems and the availability of and the need for sophisticated surgical procedures, such as cardiovascular & transplant surgery, trauma care, and therapy for cancer and blood diseases. On an average around 235 million major surgeries are being performed worldwide every year, of which 63 million are traumatic surgeries, cancer-related are over 31 million, and 10 million are related to pregnancy complications. Blood transfusion is usually prescribed in complicated childbirths to prepare for childhood congenital maternal blood disorders, acute anemia, and trauma.

Opportunity: Emerging markets

Emerging markets such as India, the Middle East, and Africa offer promising opportunities for players in the blood screening industry due to their increasing disposable incomes and improving healthcare infrastructure. For instance, according to Statista (August 2021), in 2017 India’s healthcare sector was worth about USD 160 billion, and it was estimated to reach USD 372 billion by 2022 due to rising income levels, increasing awareness about health, and the incidence of lifestyle diseases are increasing year on year. Currently, the widely used technology in India is ELISA, because NAT registered relatively low penetration. Unlike the US, Canada, most of Europe, Japan, Korea, Singapore, Sri Lanka, the UAE, South Africa, Thailand, and China, NAT is still not mandatory in India. Almost 100 blood banks, including AIIMS, PGI Chandigarh, CMC Vellore, Medanta-The Medicity, and Narayana Hrudayalaya, are using NAT in ID-NAT format, whereas around 40 blood banks are using the pooling technique. Thus, an initiative is taken by the Indian government to train doctors, hospitals, and blood banks on using NAT.

Restraint: Alternative technologies

Digital immunoassays are a one-step solution for single-molecule detection without requiring washing steps based on ELISA using an array of femtoliter-sized wells. In this assay, a biomarker molecule is conjugated with an antibody-coated magnetic microparticle seeded in a well, amplified via an enzymatic reaction, and detected with fluorescence. These tests have seen significant interest due to the urgent and ever-increasing demand for serological COVID-19 antibody tests that are inexpensive, rapid, simple, highly sensitive, quantitative, and minimally invasive. Therefore, a single-step, wash-free immunoassay for rapid and highly sensitive quantitative analysis of human serological IgG against SARS-CoV-2 has been developed, which requires only a single droplet of serum.

Challenge: High cost of blood screening technologies

Given the rise in donations of blood, awareness about blood safety, and the expenditure on healthcare across the globe, newer technologies are extensively used in high-income countries and will be adopted successfully in middle and lower-income countries in the next decade. However, many developing countries, such as India and China, currently rely on ELISA. The growth is majorly inhibited for the blood screening market for NAT in the current timeframe. The advanced tests with high costs has driven the greater use of first-generation ELISA which is older, and are less efficient tests. This test is used in many parts of the world despite its limitations. For instance, the global donor-supported cost of USD 9.98 per GeneXpert MTB/RIF cartridge is seen as unaffordable for many low and middle-income countries (LMIC) TB programs.

The blood screening market is highly consolidated. The top players— Grifols (Spain), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories, Inc. (US), bioMιrieux (France), Bio-Rad Laboratories, Inc. (US)-in the blood screening market accounted for a combined majority market share in 2020. There is a high degree of competition among the market players. Only major companies can afford high-capital investments as well as the high cost of R&D and manufacturing. This will prevent new entrants from entering this market.

In 2020, reagents & kits segment accounted for the largest share of the blood screening market, by product & service.

The blood screening market is segmented into reagents & kits, instruments, and software & services. The reagents & kits accounted for the largest share of the blood screening market in 2020, mainly there is increase in blood transfusion procedures, due to which there is more consumption and repeated use of reagents & kits in blood screening procedures.

In 2020, nucleic acid test segment accounted for the largest share in the market, by technology.

The blood screening market is segmented into nucleic acid test (NAT), enzyme-linked immunosorbent assay (ELISA), rapid tests, western blot assays, and next-generation sequencing (NGS). In 2020, the nucleic acid test (NAT) segment accounted for the largest share of the blood screening market. Factors such as the increasing adoption of NAT technology due to its higher sensitivity over other blood screening technologies and rising number of blood donations.

In 2020, blood banks and hospitals segment accounted for the largest share in the market, by end user.

The blood screening market is segmented into blood banks and hospitals. In 2020, the blood banks segment accounted for the largest share of the blood screening market. The growing number of organ transplantation surgeries is driving the growth of this segment.

North America is the largest regional market for blood screening.

The global blood screening market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the blood screening market. The North American blood screening market growth can be attributed to the increasing healthcare spending, increasing prevalence of chronic disorders, and the highly developed healthcare system in the US and Canada.

Blood Screening Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Some key players in the blood screening market (2021- 2026)

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2019–2026

Base year considered

2020

Forecast period

2021–2026

Forecast units

Value (USD)

Segments covered

Product & service, technology, end user, and region

Geographies covered

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Companies covered

Grifols (Spain), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories, Inc. (US), bioMιrieux (France), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), Beckman Coulter, Inc. (Danaher) (US), DiaSorin (Italy), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (US), Ortho Clinical Diagnostics Inc. (US), GE Healthcare (US), Merck KGaA (Germany), PerkinElmer (US), Bio-Techne Corporation (US), GFE (Germany), Trinity Biotech (Ireland), Mindray (China), Maccura Biotechnology Co., Ltd. (China), Immucor, Inc. (US), Cellabs (Australia), Abnova Corporation (Taiwan), Enzo Biochem, Inc. (US), and Cepheid (US).

This report categorizes the blood screening market into the following segments and subsegments:

By Product & Service

  • Reagents & Kits
    • NAT Reagents & Kits
      • Enzymes & Polymerases
      • Standards & Controls
      • Probes & Primers
      • Buffers, Nucleotides, and Solutions
      • Labeling & Detection Reagents
    • ELISA Reagents & Kits
      • Immunosorbents
      • Controls
      • Conjugates
      • Substrates
      • Sample Diluents & Wash Solutions
    • Other Reagents & Kits
  • Instruments
    • Rental Purchase
    • Outright Purchase
  • Software & Services

By Technology

  • Nucleic Acid Test
    • Transcription-mediated Amplification
    • Real-time PCR
  • ELISA
    • Chemiluminescent Immunoassays
    • Fluorescent  Immunoassays
    • Colorimetric Immunoassays
  • Rapid Tests
  • Western Blot Assays
  • Next-generation Sequencing

By End User

  • Blood Banks
  • Hospitals

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America
    • Australia
    • Rest of Latin America
  • Middle East & Africa

Recent Developments

  • In May 2021, Beckmann Coulter (US) launched SARS-CoV-2 IgG.
  • In September 2021, Roche Diagnostics (Switzerland) acquired TIB Molbiol Group (Germany). This acquisition will enhance Roche’s broad portfolio of molecular diagnostics solutions with a wide range of assays for infectious diseases, such as identifying SARS-CoV-2 variants.
  • In February 2020, BD (US) acquired NAT Diagnostics (US), this acquisition strengthened an early-stage company developing a molecular diagnostic platform for POC testing.

Frequently Asked Questions (FAQs):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 22)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
           1.2.2 MARKETS COVERED
                    FIGURE 1 BLOOD SCREENING MARKET SEGMENTATION
           1.2.3 YEARS CONSIDERED FOR THE STUDY
    1.3 CURRENCY
    1.4 LIMITATIONS
    1.5 STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 27)
    2.1 RESEARCH DATA
    2.2 RESEARCH APPROACH
           FIGURE 2 BLOOD SCREENING MARKET: RESEARCH DESIGN
           2.2.1 SECONDARY DATA
                    2.2.1.1 Key data from secondary sources
           2.2.2 PRIMARY DATA
                    2.2.2.1 Primary sources
                    2.2.2.2 Key data from primary sources
                    2.2.2.3 Key industry insights
                    2.2.2.4 Breakdown of primary interviews
                               FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (BLOOD SCREENING MARKET)
                               FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.3 MARKET SIZE ESTIMATION
           2.3.1 BOTTOM-UP APPROACH
                    2.3.1.1 Approach 1: Company revenue estimation approach
                               FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
                    2.3.1.2 Approach 2: Presentations of companies and primary interviews
                    2.3.1.3 Growth forecast
                    2.3.1.4 CAGR projections
                               FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           2.3.2 TOP-DOWN APPROACH
                    FIGURE 7 BLOOD SCREENING MARKET: TOP-DOWN APPROACH
    2.4 MARKET BREAKDOWN & DATA TRIANGULATION
           FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.5 MARKET SHARE
    2.6 ASSUMPTIONS FOR THE STUDY
    2.7 LIMITATIONS
    2.8 RISK ASSESSMENT
           2.8.1 RISK ASSESSMENT: BLOOD SCREENING MARKET
    2.9 GROWTH RATE ASSUMPTIONS
    2.10 COVID-19 HEALTH ASSESSMENT
    2.11 COVID-19 ECONOMIC ASSESSMENT
    2.12 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
           FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY
           FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
    2.13 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE BLOOD SCREENING MARKET

3 EXECUTIVE SUMMARY (Page No. - 44)
    FIGURE 11 BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
    FIGURE 12 BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
    FIGURE 13 BLOOD SCREENING MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
    FIGURE 14 BLOOD SCREENING MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 47)
    4.1 BLOOD SCREENING MARKET OVERVIEW
           FIGURE 15 GROWING NUMBER OF BLOOD DONATIONS AND INCREASING PREVALENCE OF INFECTIOUS DISEASES DRIVE MARKET GROWTH
    4.2 BLOOD SCREENING MARKET SHARE, BY PRODUCT & SERVICE, 2021 VS. 2026
           FIGURE 16 REAGENTS & KITS SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
    4.3 BLOOD SCREENING MARKET SHARE, BY TECHNOLOGY, 2021 VS. 2026
           FIGURE 17 NUCLEIC ACID TEST SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
    4.4 BLOOD SCREENING MARKET SHARE, BY END USER, 2021 VS. 2026
           FIGURE 18 BLOOD BANKS SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026
    4.5 BLOOD SCREENING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 19 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE BLOOD SCREENING MARKET DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 50)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 20 BLOOD SCREENING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Rising number of blood donations
                               TABLE 1 GLOBAL CANCER PREVALENCE, 2018 VS. 2025
                    5.2.1.2 Rising prevalence of infectious diseases and emergence of newer pathogens
           5.2.2 RESTRAINTS
                    5.2.2.1 Alternative technologies
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Technological advancements
                    5.2.3.2 Emerging economies offer lucrative opportunities
           5.2.4 CHALLENGES
                    5.2.4.1 High cost of blood screening technologies
                    5.2.4.2 Usage of low-sensitivity screening
    5.3 IMPACT OF COVID-19 ON THE BLOOD SCREENING MARKET
    5.4 PESSIMISTIC, OPTIMISTIC, AND REALISTIC SCENARIOS
           5.4.1 BLOOD SCREENING MARKET
                    FIGURE 21 PESSIMISTIC SCENARIO
                    FIGURE 22 OPTIMISTIC SCENARIO
                    FIGURE 23 REALISTIC SCENARIO
    5.5 PRICING ANALYSIS
           TABLE 2 PRICE OF BLOOD SCREENING PRODUCTS (2021)
    5.6 PATENT ANALYSIS
           5.6.1 PATENT ANALYSIS OF NAT
           5.6.2 PATENT ANALYSIS OF ELISA
    5.7 TRADE ANALYSIS
           5.7.1 TRADE ANALYSIS FOR DIAGNOSTIC REAGENTS
                    TABLE 3 IMPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS ON A BACKING, PREPARED DIAGNOSTIC OR LABORATORY REAGENTS, BY COUNTRY, 2016–2020 (USD MILLION)
           TABLE 4 EXPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS ON A BACKING, PREPARED DIAGNOSTIC OR LABORATORY REAGENTS, BY COUNTRY, 2016–2020 (USD MILLION)
    5.8 VALUE CHAIN ANALYSIS
           FIGURE 24 MAJOR VALUE IS ADDED DURING THE MANUFACTURING & ASSEMBLY PHASE
    5.9 SUPPLY CHAIN ANALYSIS
           FIGURE 25 BLOOD SCREENING MARKET: SUPPLY CHAIN ANALYSIS
    5.10 ECOSYSTEM ANALYSIS OF THE BLOOD SCREENING MARKET
           FIGURE 26 BLOOD SCREENING MARKET: ECOSYSTEM ANALYSIS
           5.10.1 ROLE IN ECOSYSTEM
    5.11 PORTER’S FIVE FORCES ANALYSIS
           TABLE 5 BLOOD SCREENING MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.11.1 THREAT OF NEW ENTRANTS
           5.11.2 THREAT OF SUBSTITUTES
           5.11.3 BARGAINING POWER OF BUYERS
           5.11.4 BARGAINING POWER OF SUPPLIERS
           5.11.5 DEGREE OF COMPETITION
    5.12 REGULATORY LANDSCAPE
           5.12.1 NORTH AMERICA
                    5.12.1.1 US
                    5.12.1.2 CANADA
           5.12.2 EUROPE
           5.12.3 ASIA PACIFIC
                    5.12.3.1 JAPAN
                    5.12.3.2 INDIA
           5.12.4 LATIN AMERICA
                    5.12.4.1 BRAZIL
           5.12.5 MIDDLE EAST
    5.13 CASE STUDY ANALYSIS
           5.13.1 CASE STUDY 1
           5.13.2 CASE STUDY 2
    5.14 TECHNOLOGY ANALYSIS
    5.15 TRENDS/DISRUPTIONS IMPACTING THE BUSINESS OF CUSTOMERS
           5.15.1 REVENUE SOURCES ARE SHIFTING TOWARD TECHNOLOGY-BASED SOLUTIONS DUE TO THE COVID-19 PANDEMIC
                     FIGURE 27 REVENUE SHIFT FOR THE BLOOD SCREENING MARKET

6 BLOOD SCREENING MARKET, BY PRODUCT & SERVICE (Page No. - 69)
    6.1 INTRODUCTION
           TABLE 6 BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
    6.2 REAGENTS & KITS
           TABLE 7 KEY PRODUCTS IN THE REAGENTS & KITS MARKET
           TABLE 8 BLOOD SCREENING REAGENTS & KITS MARKET, BY REGION, 2019–2026 (USD MILLION)
           TABLE 9 BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           6.2.1 NAT REAGENTS & KITS
                    6.2.1.1 High sensitivity and rising use of NAT are boosting the demand for reagents & kits
                    6.2.1.2 Enzymes & polymerases
                    6.2.1.3 Standards & controls
                    6.2.1.4 Probes & primers
                    6.2.1.5 Buffers, nucleotides, and solutions
                    6.2.1.6 Labeling & detection reagents
    6.3 PRIMARY NOTES
           6.3.1 KEY INDUSTRY INSIGHTS
                    TABLE 10 KEY PRODUCTS IN THE NAT REAGENTS & KITS MARKET
                    TABLE 11 NAT REAGENTS & KITS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 12 NAT REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           6.3.2 ELISA REAGENTS & KITS
                    6.3.2.1 Ease of use and cost-effectiveness of ELISA reagents & kits will drive the market growth
                    6.3.2.2 Immunosorbents
                    6.3.2.3 Controls
                    6.3.2.4 Conjugates
                    6.3.2.5 Substrates
                    6.3.2.6 Sample diluents & wash solutions
                               TABLE 13 KEY PRODUCTS IN THE ELISA REAGENTS & KITS MARKET
                               TABLE 14 ELISA REAGENTS & KITS MARKET, BY REGION, 2019–2026 (USD MILLION)
                               TABLE 15 ELISA REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           6.3.3 OTHER REAGENTS & KITS
                    TABLE 16 KEY PRODUCTS IN THE OTHER REAGENTS & KITS MARKET
                    TABLE 17 OTHER BLOOD SCREENING REAGENTS & KITS MARKET, BY REGION, 2019–2026 (USD MILLION)
    6.4 INSTRUMENTS
           TABLE 18 KEY PRODUCTS IN THE BLOOD SCREENING INSTRUMENTS MARKET
           TABLE 19 BLOOD SCREENING INSTRUMENTS MARKET, BY REGION, 2019–2026 (USD MILLION)
           TABLE 20 BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
           6.4.1 RENTAL PURCHASE
                    6.4.1.1 Convenience and cost-effectiveness of renting instruments has resulted in a greater end-user preference
                               TABLE 21 RENTAL PURCHASE MARKET FOR BLOOD SCREENING INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
           6.4.2 OUTRIGHT PURCHASE
                    6.4.2.1 Availability of government support will increase the outright purchase of instruments
                               TABLE 22 OUTRIGHT PURCHASE MARKET FOR BLOOD SCREENING INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
    6.5 SOFTWARE & SERVICES
           6.5.1 GROWING PURCHASE OF INSTRUMENTS WILL DRIVE DEMAND FOR SOFTWARE & SERVICES
                    TABLE 23 KEY PRODUCTS IN THE SOFTWARE & SERVICES MARKET
                    TABLE 24 BLOOD SCREENING SOFTWARE & SERVICES, BY REGION, 2019–2026 (USD MILLION)

7 BLOOD SCREENING MARKET, BY TECHNOLOGY (Page No. - 83)
    7.1 INTRODUCTION
           TABLE 25 BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
    7.2 NUCLEIC ACID TEST
           TABLE 26 KEY PRODUCTS IN THE NAT MARKET
           TABLE 27 BLOOD SCREENING MARKET FOR NAT, BY REGION, 2019–2026 (USD MILLION)
           TABLE 28 BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
           7.2.1 TRANSCRIPTION-MEDIATED AMPLIFICATION
                    7.2.1.1 High sensitivity of these assays to support the market growth
                               TABLE 29 TMA MARKET, BY REGION, 2019–2026 (USD MILLION)
           7.2.2 REAL-TIME POLYMERASE CHAIN REACTION
                    7.2.2.1 Real-time PCR provides more accurate and effective results as compared to conventional PCR
                               TABLE 30 RT-PCR MARKET, BY REGION, 2019–2026 (USD MILLION)
    7.3 ENZYME-LINKED IMMUNOSORBENT ASSAY
           TABLE 31 KEY PRODUCTS IN THE ELISA MARKET
           TABLE 32 BLOOD SCREENING MARKET FOR ELISA, BY REGION, 2019–2026 (USD MILLION)
           TABLE 33 BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
           7.3.1 CHEMILUMINESCENT IMMUNOASSAYS
                    7.3.1.1 CLIA is ultra-sensitive, automated, and a good alternative to conventional technologies
                               TABLE 34 CLIA MARKET, BY REGION, 2019–2026 (USD MILLION)
           7.3.2 FLUORESCENT IMMUNOASSAYS
                    7.3.2.1 Rising demand for safer and stable reagents and the development of novel markers to support the growth of the FIA market
                               TABLE 35 FIA MARKET, BY REGION, 2019–2026 (USD MILLION)
           7.3.3 COLORIMETRIC IMMUNOASSAYS
                    7.3.3.1 CI offers low sensitivity as it uses vulnerable/limited signal amplification strategies
                               TABLE 36 CIA MARKET, BY REGION, 2019–2026 (USD MILLION)
    7.4 RAPID TESTS
           7.4.1 RISING AWARENESS ABOUT RAPID TESTS IN EMERGING COUNTRIES TO DRIVE MARKET GROWTH
                    TABLE 37 KEY PRODUCTS IN THE RAPID TESTS TECHNOLOGY MARKET
                    TABLE 38 BLOOD SCREENING MARKET FOR RAPID TESTS, BY REGION, 2019–2026 (USD MILLION)
    7.5 WESTERN BLOT ASSAYS
           7.5.1 GROWING PREVALENCE OF TTIS IN DEVELOPING COUNTRIES HAS RESULTED IN THE INCREASED DEMAND FOR WESTERN BLOT ASSAYS
                    TABLE 39 KEY PRODUCTS IN THE WESTERN BLOT ASSAYS MARKET
                    TABLE 40 BLOOD SCREENING MARKET FOR WESTERN BLOT ASSAYS, BY REGION, 2019–2026 (USD MILLION)
    7.6 NEXT-GENERATION SEQUENCING
           7.6.1 NGS IS AN EMERGING TECHNOLOGY IN THE BLOOD SCREENING MARKET
                    TABLE 41 BLOOD SCREENING MARKET FOR NGS, BY REGION, 2019–2026 (USD MILLION)

8 BLOOD SCREENING MARKET, BY END USER (Page No. - 98)
    8.1 INTRODUCTION
           TABLE 42 BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION)
    8.2 BLOOD BANKS
           8.2.1 RISING DEMAND FOR BLOOD ATTRIBUTED TO INCREASING BLOOD DISORDER INCIDENCE
           8.2.2 KEY INDUSTRY INSIGHTS
                    TABLE 43 BLOOD SCREENING MARKET FOR BLOOD BANKS, BY REGION, 2019–2026 (USD MILLION)
    8.3 HOSPITALS
           8.3.1 INCREASING SURGICAL PROCEDURES WILL DRIVE THE GROWTH OF THE HOSPITALS SEGMENT
                    TABLE 44 BLOOD SCREENING MARKET FOR HOSPITALS, BY REGION, 2019–2026 (USD MILLION)

9 BLOOD SCREENING MARKET, BY REGION (Page No. - 102)
    9.1 INTRODUCTION
           TABLE 45 BLOOD SCREENING MARKET, BY REGION, 2019–2026 (USD MILLION)
    9.2 NORTH AMERICA
           FIGURE 28 NORTH AMERICA: BLOOD SCREENING MARKET SNAPSHOT
           TABLE 46 NORTH AMERICA: BLOOD SCREENING MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 47 NORTH AMERICA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 48 NORTH AMERICA: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 49 NORTH AMERICA: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
           TABLE 50 NORTH AMERICA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
           TABLE 51 NORTH AMERICA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 52 NORTH AMERICA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
           TABLE 53 NORTH AMERICA: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.2.1 US
                    9.2.1.1 The US dominated the North American blood screening market in 2020
                               TABLE 54 INCIDENCE OF VARIOUS CANCERS IN THE US, 2018 VS. 2025
                               TABLE 55 US: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                               TABLE 56 US: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 57 US: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
                               TABLE 58 US: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                               TABLE 59 US: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 60 US: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
                               TABLE 61 US: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Growing volume of surgical procedures performed and high burden of cancer to support market growth
                               TABLE 62 CANADA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                               TABLE 63 CANADA: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 64 CANADA: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
                               TABLE 65 CANADA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                               TABLE 66 CANADA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 67 CANADA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
                               TABLE 68 CANADA: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION)
    9.3 EUROPE
           TABLE 69 EUROPE: BLOOD SCREENING MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 70 EUROPE: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 71 EUROPE: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 72 EUROPE: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
           TABLE 73 EUROPE: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
           TABLE 74 EUROPE: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 75 EUROPE: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
           TABLE 76 EUROPE: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 Higher healthcare spending and increase in cancer prevalence drives market growth
                               TABLE 77 GERMANY: KEY MACROINDICATORS
                               TABLE 78 GERMANY: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                               TABLE 79 GERMANY: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 80 GERMANY: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
                               TABLE 81 GERMANY: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                               TABLE 82 GERMANY: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 83 GERMANY: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
                               TABLE 84 GERMANY: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.3.2 FRANCE
                    9.3.2.1 Increasing prevalence of HIV to support the market growth
                               TABLE 85 FRANCE: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                               TABLE 86 FRANCE: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 87 FRANCE: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
                               TABLE 88 FRANCE: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                               TABLE 89 FRANCE: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 90 FRANCE: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
                               TABLE 91 FRANCE: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.3.3 UK
                    9.3.3.1 Government support to prevent transmission of HIV and other infections will drive market growth
                               TABLE 92 UK: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                               TABLE 93 UK: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 94 UK: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
                               TABLE 95 UK: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                               TABLE 96 UK: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 97 UK: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
                               TABLE 98 UK: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.3.4 ITALY
                    9.3.4.1 Italy is witnessing an increase in the number of blood donors
                               TABLE 99 ITALY: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                               TABLE 100 ITALY: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 101 ITALY: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
                               TABLE 102 ITALY: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                               TABLE 103 ITALY: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 104 ITALY: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
                               TABLE 105 ITALY: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.3.5 SPAIN
                    9.3.5.1 Increasing adoption of NAT technology will support market growth
                               TABLE 106 SPAIN: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                               TABLE 107 SPAIN: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 108 SPAIN: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
                               TABLE 109 SPAIN: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                               TABLE 110 SPAIN: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 111 SPAIN: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
                               TABLE 112 SPAIN: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.3.6 REST OF EUROPE
                    TABLE 113 ROE: HEALTHCARE EXPENDITURE, BY COUNTRY, 2010 VS. 2018 (% OF GDP)
                    TABLE 114 ROE: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                    TABLE 115 ROE: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 116 ROE: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
                    TABLE 117 ROE: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                    TABLE 118 ROE: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 119 ROE: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
                    TABLE 120 ROE: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION)
    9.4 ASIA PACIFIC
           FIGURE 29 ASIA PACIFIC: BLOOD SCREENING MARKET SNAPSHOT
           TABLE 121 ASIA PACIFIC: BLOOD SCREENING MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 122 ASIA PACIFIC: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 123 ASIA PACIFIC: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 124 ASIA PACIFIC: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
           TABLE 125 ASIA PACIFIC: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
           TABLE 126 ASIA PACIFIC: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 127 ASIA PACIFIC: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
           TABLE 128 ASIA PACIFIC: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.4.1 CHINA
                    9.4.1.1 China has a high prevalence of infectious diseases
                               TABLE 129 CHINA: KEY MACROINDICATORS
                               TABLE 130 CHINA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                               TABLE 131 CHINA: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 132 CHINA: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
                               TABLE 133 CHINA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                               TABLE 134 CHINA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 135 CHINA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
                               TABLE 136 CHINA: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.4.2 JAPAN
                    9.4.2.1 Rising geriatric population and prevalence of cancer support market growth
                               TABLE 137 JAPAN: KEY MACROINDICATORS
                               TABLE 138 JAPAN: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                               TABLE 139 JAPAN: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 140 JAPAN: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
                               TABLE 141 JAPAN: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                               TABLE 142 JAPAN: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 143 JAPAN: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
                               TABLE 144 JAPAN: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.4.3 INDIA
                    9.4.3.1 Increasing number of road accidents and rise in prevalence of thalassemia will support the market growth
                               TABLE 145 INDIA: KEY MACROINDICATORS
                               TABLE 146 INDIA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                               TABLE 147 INDIA: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 148 INDIA: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
                               TABLE 149 INDIA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                               TABLE 150 INDIA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 151 INDIA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
                               TABLE 152 INDIA: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.4.4 AUSTRALIA
                    9.4.4.1 Increased demand for blood donations will propel market growth
                               TABLE 153 AUSTRALIA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                               TABLE 154 AUSTRALIA: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 155 AUSTRALIA: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
                               TABLE 156 AUSTRALIA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                               TABLE 157 AUSTRALIA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 158 AUSTRALIA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
                               TABLE 159 AUSTRALIA: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.4.5 REST OF ASIA PACIFIC
                    TABLE 160 ROAPAC: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                    TABLE 161 ROAPAC: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 162 ROAPAC: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
                    TABLE 163 ROAPAC: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                    TABLE 164 ROAPAC: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 165 ROAPAC: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
                    TABLE 166 ROAPAC: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION)
    9.5 LATIN AMERICA
           TABLE 167 LATIN AMERICA: BLOOD SCREENING MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 168 LATIN AMERICA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 169 LATIN AMERICA: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 170 LATIN AMERICA: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
           TABLE 171 LATIN AMERICA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
           TABLE 172 LATIN AMERICA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 173 LATIN AMERICA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
           TABLE 174 LATIN AMERICA: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.5.1 BRAZIL
                    9.5.1.1 Increased prevalence of cancer will support the market growth
                               TABLE 175 INCIDENCE OF VARIOUS CANCERS IN BRAZIL, 2020 VS. 2025
                               TABLE 176 BRAZIL: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                               TABLE 177 BRAZIL: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 178 BRAZIL: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
                               TABLE 179 BRAZIL: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                               TABLE 180 BRAZIL: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 181 BRAZIL: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
                               TABLE 182 BRAZIL: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.5.2 REST OF LATIN AMERICA
                    TABLE 183 ROLATAM: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                    TABLE 184 ROLATAM: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 185 ROLATAM: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
                    TABLE 186 ROLATAM: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                    TABLE 187 ROLATAM: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 188 ROLATAM: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
                    TABLE 189 ROLATAM: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION)
    9.6 MIDDLE EAST & AFRICA
           9.6.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND STRENGTHENING OF HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
                    TABLE 190 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                    TABLE 191 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 192 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
                    TABLE 193 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                    TABLE 194 MIDDLE EAST & AFRICA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 195 MIDDLE EAST & AFRICA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
                    TABLE 196 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION)

10 COMPETITIVE LANDSCAPE (Page No. - 167)
     10.1 OVERVIEW
     10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
             10.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN THE BLOOD SCREENING MARKET
                        TABLE 197 OVERVIEW OF STRATEGIES DEPLOYED BY KEY BLOOD SCREENING MANUFACTURING COMPANIES
     10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
             FIGURE 30 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE BLOOD SCREENING MARKET
     10.4 MARKET SHARE ANALYSIS
             FIGURE 31 BLOOD SCREENING MARKET SHARE, BY KEY PLAYER (2020)
             TABLE 198 BLOOD SCREENING MARKET: DEGREE OF COMPETITION
     10.5 COMPANY EVALUATION QUADRANT
             10.5.1 LIST OF EVALUATED VENDORS
             10.5.2 STARS
             10.5.3 EMERGING LEADERS
             10.5.4 PERVASIVE PLAYERS
             10.5.5 PARTICIPANTS
                        FIGURE 32 BLOOD SCREENING MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020
     10.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2020)
             10.6.1 PROGRESSIVE COMPANIES
             10.6.2 STARTING BLOCKS
             10.6.3 RESPONSIVE COMPANIES
             10.6.4 DYNAMIC COMPANIES
                        FIGURE 33 BLOOD SCREENING MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2020
     10.7 COMPETITIVE BENCHMARKING
             10.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS
                        FIGURE 34 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN THE BLOOD SCREENING MARKET
                        TABLE 199 PRODUCT FOOTPRINT OF COMPANIES
                        TABLE 200 REGIONAL FOOTPRINT OF COMPANIES
     10.8 COMPETITIVE SCENARIO
             10.8.1 PRODUCT LAUNCHES & REGULATORY APPROVALS
                        TABLE 201 KEY PRODUCT LAUNCHES
             10.8.2 DEALS
                        TABLE 202 KEY DEALS

11 COMPANY PROFILES (Page No. - 177)
(Business Overview, Products, Key Insights, Recent Developments, MnM View)* 
     11.1 KEY PLAYERS
             11.1.1 F. HOFFMANN-LA ROCHE
                        TABLE 203 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW
                        FIGURE 35 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2020)
             11.1.2 GRIFOLS
                        TABLE 204 GRIFOLS: BUSINESS OVERVIEW
                        FIGURE 36 GRIFOLS: COMPANY SNAPSHOT (2020)
             11.1.3 ABBOTT LABORATORIES
                        TABLE 205 ABBOTT LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 37 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
             11.1.4 BIOMΙRIEUX
                        TABLE 206 BIOMΙRIEUX: BUSINESS OVERVIEW
                        FIGURE 38 BIOMΙRIEUX: COMPANY SNAPSHOT (2020)
             11.1.5 BIO-RAD LABORATORIES
                        TABLE 207 BIO-RAD LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 39 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2020)
             11.1.6 BECTON, DICKINSON AND COMPANY
                        TABLE 208 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
                        FIGURE 40 BD: COMPANY SNAPSHOT (2020)
             11.1.7 DANAHER CORPORATION
                        TABLE 209 DANAHER CORPORATION.: BUSINESS OVERVIEW
                        FIGURE 41 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
             11.1.8 DIASORIN
                        TABLE 210 DIASORIN: BUSINESS OVERVIEW
                        FIGURE 42 DIASORIN: COMPANY SNAPSHOT (2020)
             11.1.9 SIEMENS HEALTHINEERS
                        TABLE 211 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW
                        FIGURE 43 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2020)
             11.1.10 THERMO FISHER SCIENTIFIC, INC.
                        TABLE 212 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
                        FIGURE 44 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020)
(Business Overview, Products, Key Insights, Recent Developments, MnM View)* 
     11.2 OTHER PLAYERS
             11.2.1 ORTHO CLINICAL DIAGNOSTICS, INC.
             11.2.2 GE HEALTHCARE
             11.2.3 MERCK KGAA
             11.2.4 PERKINELMER
             11.2.5 BIO-TECHNE CORPORATION
             11.2.6 GFE
             11.2.7 TRINITY BIOTECH
             11.2.8 J. MITRA & CO. PVT. LTD.
             11.2.9 MINDRAY
             11.2.10 MACCURA BIOTECHNOLOGY CO., LTD.
             11.2.11 IMMUCOR, INC.
             11.2.12 CELLABS
             11.2.13 ABNOVA CORPORATION
             11.2.14 ENZO BIOCHEM, INC.
             11.2.15 CEPHEID

12 APPENDIX (Page No. - 228)
     12.1 DISCUSSION GUIDE
     12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     12.3 AVAILABLE CUSTOMIZATIONS
     12.4 RELATED REPORTS
     12.5 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the blood screening market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.

Blood Screening Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the blood screening market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the blood screening market have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Global Blood screening Market Size: Top-Down Approach

Blood Screening Market Size, and Top-Down Approach

Data Triangulation

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, segment, and forecast the global blood screening market by product & service, technology, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall blood screening market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze company developments such as product launches, agreements, partnerships, and acquisitions in the blood screening market
  • To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Country Information

  • Blood screening market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific, Latin America, and Middle East & Africa

Company profiles

  • Additional five company profiles of players operating in the blood screening market.
Report Code
MD 3687
Published ON
Nov, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Blood Screening Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback